|
|
|
|
|
|
|
18.03.26 - 21:06
|
Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026 (GlobeNewswire EN)
|
|
|
CAMBRIDGE, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and diseases with high unmet need, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2025, and provide a business update on Thursday, March 26, 2026, after market close. The Company does not intend to host a conference call....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
19.12.25 - 14:03
|
Spero Announces NDA Resubmission of Tebipenem HBr by GSK to the FDA for the Treatment of Complicated Urinary Tract Infections, Including Pyelonephritis (GlobeNewswire EN)
|
|
|
CAMBRIDGE, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that its development partner, GSK, filed a New Drug Application (NDA) resubmission to the U.S. Food and Drug Administration (FDA) for tebipenem HBr, an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis. The NDA submission triggers a $25 million milestone payment to Spero, expected to be received in Q1 2026....
|
|
|
28.11.25 - 14:03
|
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
|
|
|
CAMBRIDGE, Mass., Nov. 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on November 3, 2025, the Compensation Committee of Spero's Board of Directors approved the grant of an aggregate of 90,000 restricted stock unit awards (RSUs) to one new employee under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended (2019 Inducement Plan). The RSUs are being granted as an inducement material to Spero's new employee in accordance with Nasdaq Listing Rule 5635(c)(4)....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
28.05.25 - 15:45
|
Spero Therapeutics-Aktie +300%: Jubelsturm bei NBC-Anlegern! (Sharedeals)
|
|
|
Ein Tag, der in die Annalen des exklusiven No Brainer Club (NBC) eingehen wird: Aus dem Nichts schießt die Aktie des Biotech-Unternehmens Spero Therapeutics nach positiven Daten-News vorbörslich um bis zu +300% durch die Decke und kurz darauf zündet noch eine weitere Kursrakete. Der Jubel im Anlegerkreis kennt keine Grenzen mehr! Wirkstoff Tebipenem vor Zulassung […]
The post Spero Therapeutics-Aktie +300%: Jubelsturm bei NBC-Anlegern! first appeared on sharedeals.de....
|
|
|
28.05.25 - 14:18
|
Pre-market Movers: SPRO, SGBX, BROG, LVWR, CETX. (RTTNews)
|
|
|
Massachusetts-based Spero Therapeutics, Inc. (SPRO), a clinical-stage biopharmaceutical company is up over 224 percent in Wednesday's pre-market trading. The following are some of the other stocks making big moves in Wednesday's pre-market trading....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
